Please login to the form below

Not currently logged in


This page shows the latest Zulresso news and features for those working in and with pharma, biotech and healthcare.

Sage slides off a MOUNTAIN as depression drug flunks trial

Sage slides off a MOUNTAIN as depression drug flunks trial

SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... With analysts suggesting that Zulresso’s high cost ($34, 000 at US list price) and

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...